v3.25.4
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2026
Jan. 31, 2025
Income Statement [Abstract]        
Revenue, Product and Service [Extensible List] Service [Member] Service [Member] Service [Member] Service [Member]
Oncology revenue $ 16,559 $ 17,039 $ 45,590 $ 44,589
Costs and operating expenses:        
Cost, Product and Service [Extensible List] Service [Member] Service [Member] Service [Member] Service [Member]
Cost of oncology revenue $ 8,834 $ 6,617 $ 24,090 $ 21,118
Research and development 2,271 1,719 6,969 4,862
Sales and marketing 2,666 1,806 6,520 5,236
General and administrative 2,975 2,398 8,519 6,813
Loss on sale and disposal of equipment 89 0 110 0
Total costs and operating expenses 16,835 12,540 46,208 38,029
Income (loss) from operations (276) 4,499 (618) 6,560
Other income, net 39 19 184 30
Income (loss) before provision for income taxes (237) 4,518 (434) 6,590
Provision for income taxes 42 23 74 54
Net income (loss) attributable to Company's common shares $ (279) $ 4,495 $ (508) $ 6,536
Net income (loss) per common share outstanding        
basic (in dollars per share) $ (0.02) $ 0.33 $ (0.04) $ 0.48
diluted (in dollars per share) $ (0.02) $ 0.31 $ (0.04) $ 0.46
Weighted average common shares outstanding        
basic (in shares) 13,886,797 13,700,627 13,805,647 13,620,686
and diluted (in shares) 13,886,797 14,364,904 13,805,647 14,132,712